Sep 9, 2026 07:27AM
Sep 8, 2026 06:50AM
Sep 8, 2026 06:50AM
Sep 3, 2026 06:51AM
Sep 3, 2026 06:50AM
Aug 14, 2026 06:46AM
Aug 13, 2026 04:04AM Pharvaris B.V. (PHVS) PT Raised to $75 at Citizens: Has Cash Runway Into 2028
Aug 12, 2026 06:50AM
Aug 6, 2026 06:51AM
Aug 6, 2026 06:50AM
Jul 22, 2026 06:50AM
Jul 22, 2026 06:50AM
Jul 22, 2026 06:50AM
Jul 15, 2026 05:11AM Wells Fargo Starts Pharvaris B.V. (PHVS) at Overweight
Jul 6, 2026 06:50AM
Jul 6, 2026 06:50AM
Jun 15, 2026 06:50AM
Jun 15, 2026 06:50AM
May 12, 2026 04:05PM
May 8, 2026 06:01AM
May 8, 2026 06:00AM Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
Apr 20, 2026 06:50AM
Apr 20, 2026 06:50AM
Apr 2, 2026 06:50AM
Mar 20, 2026 06:51AM
Mar 20, 2026 06:50AM
Mar 11, 2026 06:50AM
Mar 11, 2026 06:50AM Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
Mar 11, 2026 06:50AM
Mar 2, 2026 06:55AM
Mar 2, 2026 06:50AM
Jan 12, 2026 06:50AM
Jan 12, 2026 06:50AM
Dec 3, 2025 06:50AM
Dec 3, 2025 06:50AM Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
Nov 12, 2025 06:50AM
Nov 10, 2025 06:50AM
Aug 12, 2025 04:05PM
Jul 10, 2025 06:51AM
Jul 10, 2025 06:50AM
Jun 16, 2025 06:50AM
Jun 16, 2025 06:50AM Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
Jun 2, 2025 06:52AM
Jun 2, 2025 06:50AM
May 13, 2025 04:05PM
Apr 7, 2025 06:58AM
Apr 1, 2025 06:50AM
Apr 1, 2025 06:50AM
Mar 3, 2025 06:50AM Pharvaris (PHVS) Presents Long-Term Clinical Data of Deucrictibant
Mar 3, 2025 06:50AM

330,739 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All